Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2

CML is effectively treated with tyrosine kinase inhibitors (TKIs). However, the efficacy of these drugs is confined to the chronic phase of the disease and development of resistance to TKIs remains a pressing issue. The anti-inflammatory COX2 inhibitor celecoxib has been utilized as anti-tumour drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Riva, Beatrice, Dominici, Marco De, Gnemmi, Ilaria, Mariani, Samanta A., Minassi, Alberto, Minieri, Valentina, Salomoni, Paolo, Canonico, Pier Luigi, Genazzani, Armando A., Calabretta, Bruno, Condorelli, Fabrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348412/
https://www.ncbi.nlm.nih.gov/pubmed/27835591
http://dx.doi.org/10.18632/oncotarget.13146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348412/
https://www.ncbi.nlm.nih.gov/pubmed/27835591
http://dx.doi.org/10.18632/oncotarget.13146

Ejemplares similares